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A B S T R A C T
Purpose: Sulthiame is an old antiepileptic drug primarily used in a few European countries for the
treatment of benign epilepsy of childhood with central temporal spikes. Other studies suggest that it
might be effective in children and adults with a range of refractory seizure types.
Methods: A retrospective case note review was undertaken to evaluate the efﬁcacy and safety of
sulthiame as adjunctive therapy in children with refractory epilepsies.
Results: Twenty patients (10 female) were evaluated, aged 10.7 (range 2.1–17) years. The median
duration of treatment with sulthiame was 18 (range 2–37) months. Fifty ﬁve percent of patients showed
at least a 50% reduction in seizure frequency and two patients were seizure-free at the end of follow-up.
Patients with focal seizures responded best. Seven patients reported side effects, leading to withdrawal
of the drug in two (10%).
Conclusion: Sulthiame was reasonably effective and well-tolerated in a heterogeneous group of 20
children with refractory epilepsies. Although an ‘old’ antiepileptic drug it should be considered in a
similar population.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Sulthiame (STM), a carbonic anhydrase inhibitor, became
established as an antiepileptic drug (AED) in the treatment of
partial (focal) epilepsies in the 1950s. Over the subsequent half-
century it has been reported to be effective as adjunctive therapy
or monotherapy in benign partial epilepsy with centro-temporal
spikes (BECTS),1,2 other, non-BECTS focal epilepsies,3 children with
refractory epilepsy3–5 adults with refractory epilepsy and learning
difﬁculties,6 adults with refractory focal and/or secondarily
generalised seizures,7 juvenile myoclonic epilepsy and other
myoclonic seizures,3,8 infantile spasms,9 Rett syndrome10 and
continuous spike waves in slow-wave sleep.11 The drug has also
been reported to either normalise, or markedly improve the
abnormal electroencephalographic (EEG) activity in BECTS.12,13
There have been conﬂicting reports of its effect on cognitive
function.
Studies in the late 1960s showed that the metabolism of
phenytoin was inhibited by STM resulting in an elevation of
phenytoin blood levels and possible toxicity.14 This led to the
perception that STM might have no independent anticonvulsant* Corresponding author. Tel.: +44 151 252 5375.
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doi:10.1016/j.seizure.2011.08.006efﬁcacy which was only partly refuted following publication of a
double-blind randomised trial of STM and phenytoin15 and limited
data that it may have independent sodium channel-blocking (and
therefore anticonvulsant) activity.16,17 This perception, together
with concerns over its adverse side-effect proﬁle led to the marked
decline of the use of STM in routine practice, other than in a few
countries in Europe. This might in part explain the relative scarcity
of reports of its use in treating children with refractory epilepsy.3–5
The aim of this paper is to report the efﬁcacy and safety of STM
in a heterogeneous group of children with refractory epilepsies.
2. Patients and methods
This was a retrospective study on the use of STM in children
with refractory epilepsy. Patients were identiﬁed from the epilepsy
clinics of three consultant paediatric neurologists at this institu-
tion between July 2007 and August 2010. A patient was considered
to be refractory if they had failed to respond to at least two
previously prescribed AEDs in appropriate and optimal doses and
who had experienced at least one seizure per month in the 12
months prior to the introduction of the drug.
Medical records were reviewed and clinical information was
recorded on a standard proformas including age of the onset of
epilepsy; seizure type; epilepsy syndrome; underlying cause;
presence of learning difﬁculties; prior and current AED history;vier Ltd. All rights reserved.
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duration of treatment.
The epilepsy syndromes were classiﬁed according to the 1989
International League Against Epilepsy (ILAE) classiﬁcation.
The efﬁcacy of STM was assessed based on seizure frequency
determined by seizure diaries completed by caregivers. The
baseline seizure frequency was obtained from the case notes at
the time STM was ﬁrst prescribed. Response rates were assessed at
the following times: three and 12 months after starting STM, at the
time any decision was made to withdraw STM and at the last
recorded follow-up for those who remained on the drug. A
judgement on the relative change in seizure frequency was
assessed from the case notes or clinic letters and was documented
as follows: seizure free (deﬁned as no seizures for a minimum of 12
months); >50% reduction in seizure frequency; some improve-
ment (25–50%); no signiﬁcant response (0–24%) and increased
seizures.
Tolerability was assessed by recording any documented
unwanted side-effects and reasons for discontinuation of STM
were recorded.
Laboratory investigations were undertaken if clinically indicat-
ed. Routine EEG recordings and neuro-cognitive assessments were
not obtained sequentially during the patient’s treatment with
STM; however, repeat EEGs were undertaken in patients with
continuous spike wave activity in slow wave sleep.
Data analysis was descriptive.
3. Results
3.1. Patient characteristics
Twenty children (10 females) were evaluated in this study.
Patients were classiﬁed according to seizure type (generalised,
focal or mixed), aetiology (idiopathic, cryptogenic or symptomatic)
and epilepsy syndrome (Table 1). Fourteen of the 20 (70%) patients
had learning difﬁculties, severe in ﬁve; 18 of the 20 patients had
undergone formal assessments of cognitive function including
with age-appropriate Wechsler examinations.
Eighteen patients had failed to achieve acceptable seizure
control on a minimum of three previous AEDs (median 7.7; range
2–9); two patients had received only two AEDs prior to
commencing STM. Sulthiame was started as adjunctive therapy
in all 20 patients. The median number of concomitant AEDs used
was 1.2 (range 1–3) with the most commonly prescribed being
valproate and clobazam (Table 2). During the study, concomitantTable 1
Demographic and clinical characteristics of the 20 patients.
Characteristic N (%)
Mean (range) age in years 10.7 (2.1–17)
Generalised seizures: 4 (20)
Idiopathic 1 (5)
Myoclonic-astatic epilepsy
Cryptogenic 2 (10)
No syndrome 1
Lennox-Gastaut syndrome 1
Symptomatic 1
CDKL5 mutation
Focal seizures: 15 (70)
Cryptogenic 6 (30)
Symptomatic 9 (45)
Focal cortical dysplasia 6 (30)
Tuberous sclerosis 1
Porencephaly 1
Periventricular leucomalacia 1
Mixed (generalised and focal seizures): 1 (5%)
Dravet syndrome 1antiepileptic medication was able to be withdrawn in three
patients.
One patient had undergone a frontal, fronto-parietal and
temporal resection four months prior to the introduction of STM
for extensive cortical dysplasia. Three patients had undergone
insertion of a vagal nerve stimulator (VNS) four, six and eight
months prior to the commencement of STM and one patient had
been started on a ketogenic diet ﬁve months before the
introduction of STM, without any improvement in seizure control.
The median duration of STM treatment was 18 months (range
2–37 months). The median ﬁnal maintenance dose was 8.2 (range
2–12) mg/kg/day.
3.2. Efﬁcacy
Three patients (15%) discontinued STM before three months,
two because of an increase in seizure frequency (focal and
secondary generalised tonic–clonic) and one patient reported
increased focal seizures and unacceptable drowsiness. One patient
was followed up for only two months and two weeks and excluded
from the analysis. The median length of follow-up for the
remaining 16 patients was 19 (range 4–37 months) months.
Fourteen of the 16 patients (70%) demonstrated a reduction in
seizure frequency of >50% at the ﬁrst follow-up period (three
months). However, seizure control subsequently deteriorated in
four of these 16 patients (20% of the whole group) at eight, 11, 18
and 20 months after the introduction of STM and the drug was
withdrawn.
Two patients showed a seizure reduction of 25–50%.
No patient developed a new seizure type during the study.
Three patients (15%) became seizure free, two remaining so
following discontinuation of concomitant AEDs. One was an 11
year old girl with learning difﬁculties, focal cryptogenic epilepsy
and continuous spike wave activity in slow wave sleep (CSWSS)
who had been seizure-free for 14 months at the end of the study
and on a maintenance dose of 15 mg/kg/day. Overnight EEG
undertaken two months after starting STM showed resolution of
CSWSS. The other patient was an 11 year old boy, with
cryptogenic focal epilepsy who had been seizure-free for 16
months at the end of the study and receiving a maintenance
dose of 7.5 mg/kg/day. Seizure-freedom was lost in the
remaining 13 year-old boy after 11 months but seizure-
reduction was still >90% at 19 months on a maintenance dose
of 6.5 mg/kg/day when the study ended.
Patients who showed the best response with >50% reduction in
seizures, included those with focal cryptogenic epilepsy (ﬁve of six
patients, 83%) and focal symptomatic epilepsy (six of nine patients,
66%) (Table 3). Only two of the four patients with a generalised
epilepsy, including one patient with Lennox-Gastaut syndrome
showed >50% reduction; however, both patients subsequently
showed deterioration after 18 months of treatment.Table 2
Concomitant antiepileptic drugs in the 20 patients.
Antiepileptic drug Patient number (%)
Valproate 6 (30)
Clobazam 6 (30)
Levetiracetam 5 (25)
Carbamazepine 4 (20)
Lamotrigine 2 (10)
Nitrazepam 1 (5)
Oxcarbazepine 1 (5)
Phenytoin 1 (5)
Ruﬁnamide 1 (5)
Zonisamide 1 (5)
Topiramate 1 (5)
Table 3
Response by seizure type.
Seizure type Number of patients >50% reduction 25–50% reduction 0–24% reduction Increase in seizure frequency
Focal 16 14 1 0 1
Secondary GTC 14 11 1 1 1
Absences (atypical) 6 1 – 5 –
Myoclonic 5 – 1 2 2
Tonic 3 – – 2 1
Primary GTC 2 1 – – 1
Atonic 2 – – 1 1
GTCS: generalised tonic–clonic seizures.
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concomitant AEDs prescribed precluded any conclusion as to
whether any speciﬁc combination with STM was more or less
effective.
3.3. Tolerability
Thirteen (65%) of the 20 patients and 11 (55%) remained on
treatment at 12 months and at 37 months respectively, on
completion of the study. Nine (45%) patients discontinued
treatment; four (20%) because of lack of therapeutic beneﬁt;
two (10%) an increase in seizure frequency; two (10%) because of
an increase in seizure frequency and side effects; and in one (5%)
because of lack of efﬁcacy and side effects; in one (5%). Side-effects
which contributed to the withdrawal of STM in the two patients
included cognitive impairment and drowsiness; the maximum
dose of STM in these patients was 6.2 and 7.4 mg/kg, respectively.
Seven patients (35%) reported at least one unacceptable and
unwanted side-effect, most of which were mild and which resolved
on reduction of dosage other than the two patients described
above. The most frequently reported side-effect was drowsiness
(two patients, 10%); one patient each complained of cognitive
slowing, hypersalivation, breathlessness and tachypnoea and
diarrhoea. The maximum dose of STM in patients who experienced
side effects was 9.8 mg/kg.
4. Discussion
Despite the introduction of at least 10 new anti-epileptic drugs
since 1990, at least 25% of children with epilepsy remain
refractory. There may be a reluctance to prescribe older AEDs
because of the perception that they may have been less effective or
may have been associated with unacceptable adverse side-effects,
or both. This phenomenon may have applied, and still apply, to
STM. Previous reports on the efﬁcacy of STM and its continuing use
in a number of countries encouraged the epilepsy unit in this
institution to prescribe the drug in children with refractory
epilepsy.
In this retrospective analysis of the STM-treated patients, 13
patients (65%) showed greater than 50% reduction in seizure
frequency at one year follow-up. With longer follow-up, the drug’s
efﬁcacy and tolerability was maintained in 11 (55%) patients,
including the two patients who became seizure-free (and who had
remained so for over 12 months at the end of follow-up). This is
higher than the 42% responder rate observed in the one adult
study undertaken in a larger population with predominantly focal
seizures and with heterogeneous aetiologies and learning
difﬁculties6 and 17.8% in 28 adult patients treated in a German
study.7
A Japanese study (written in Japanese) reported 26 children
aged less than 18 years with intractable generalised and focal
epilepsies who received STM in doses of 4–14 mg/kg/day.5 Two
patients became seizure free and eight demonstrated a >50%reduction in seizure frequency; however, six of these 10 patients
developed ‘‘tolerance’’ with loss of seizure control. A study
undertaken by the national epilepsy centre in Norway and
published in abstract form reported that seven (46%) of 15
children with refractory epilepsy treated with STM showed >75%
reduction in seizures; there was no information on duration of
follow-up and tolerability.4 In a retrospective study of 125 children
with different types of epilepsy treated with STM, four of seven
patients with symptomatic focal epilepsy showed >50% seizure
reduction, but there was no further information on these patients.3
Sulthiame appeared to be particularly effective in treating focal
seizures with 14 (88%) of the 16 patients with focal seizures
demonstrating >50% reduction. This is similar to the adult study6
and other paediatric studies of STM in BECTS,1–3,13 occipital
epilepsy18 and other focal seizures/epilepsies.3 In contrast, ﬁve of
eight patients (63%) with generalised, but only two of seven
patients (29%) with focal seizures showed >75% seizure reduction
respectively in the Norwegian study.4 One of our patients with
learning difﬁculties showed resolution of CSWSS and had been
seizure-free on STM monotherapy for 14 months at the end of the
study.
Sulthiame has been reported to be effective in the treatment of
myoclonic seizures.3,8 This was not reﬂected in the ﬁve patients
with this seizure type in the current study but the small number of
patients precludes any meaningful comment or conclusion on this
issue.
Limited data suggest that its efﬁcacy may be related to the
dose2–4 and this was reﬂected in the current study; the median
dose of STM in those showing >50% seizure-reduction (8.9 mg/kg)
was higher than compared to the rest of the group (7.6 mg/kg). This
might suggest that further dose increases may be justiﬁed,
providing it is well-tolerated.
Sulthiame was well-tolerated in the current study with only
two of 20 patients discontinuing the drug because of unacceptable
side-effects. This retention rate is comparable to that reported for
the newer AEDs.19,20 The incidence of side effects of STM (35%) was
lower when compared to an earlier study2 but considerably higher
than that observed in an adult study.7 This could in part, reﬂect the
fact that most of our patients had moderate or severe learning
difﬁculties and may not have been able to verbalise the more
commonly reported side-effects associated with STM (cognitive
slowing and a feeling of breathlessness or tachypnoea). One patient
with no learning difﬁculty did show some cognitive difﬁculties,
which resolved when the dose was reduced from 12 to just under
10 mg/kg/day although the drug was subsequently discontinued
because of poor seizure control. Cognitive impairment has been
reported previously21 although it has been disputed that this may
have been an effect of BECTS rather than the drug itself.22
Side-effects seem to be dose-related.2,15,23 This was supported
by the current study; the median dose in patients who reported
side-effects was slightly higher (9.8 mg/kg) than those who did not
(8.2 mg/kg). The doses used in this study are higher than those
used in European studies,2,13 and particularly in those countries
N. Swiderska et al. / Seizure 20 (2011) 805–808808(Germany, Switzerland) where STM is routinely prescribed for
BECTS, but considerably lower than one of the earliest studies.15
This study clearly has number of limitations. First, it is
retrospective and involves a small number of patients. Second, it
assesses a very heterogeneous group of children which precludes
any conclusion as to which seizure type (or types) is (are) most
likely to respond best. Third, the study did not use any serial and
formal assessments of cognitive function. Despite these limitations
the results suggest that treatment with STM may be associated
with a signiﬁcant and sustained improvement in seizure control in
children with refractory epilepsy and particularly those with
refractory focal seizures.
In conclusion, STM, despite being an ‘old’ AED seems to have
good efﬁcacy, a relatively good safety proﬁle, does not require
blood-monitoring and could be considered as an additional
treatment option in children with refractory epilepsy. However,
it remains unclear as to exactly when it should be prescribed in
children with refractory, and particularly focal, epilepsy.
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